Laboratory ofGastroenterology & Hepatology, Ministry of PublicHealth

Our Laboratory was founded in 1994. Since then thelaboratory has developed arduously and extensively by conforming inthe motto of “Austerity, Practicality, Unity and Creativity”, andhas become one of the top research institutes in CHINA.The numberof staff in the laboratory is more than 100, including 8 professorsand 10 associate professors. There are two research divisions,Gastroenterology and Hepatology, as well as several laboratories,i.e. molecular pathology, cell biology, molecular biology,biochemistry, immunology, gut hormones, gastrointerstinalphysiology,pharmacology, microbiology (Parvovirus H-1 and H.pylori), flow cytometry. The research interest is mainly focused onchronic gastric disease and chronic liver disease. About 50 grantswere gained and 30 prizes of science and technology were awardedfrom the State, the Ministry of Public Health and/or the Shanghaimunicipality in the past ten years. More than 400 papers and 20books were published in English and Chinese. Over 100 studentsstudied for Ph.D. or master’s degree have completed theirtraining courses and research programs. Our laboratory has academiccontacts with many universities and institutes in USA, Japan,Australia, Netherlands, France, German and Norway. About 50scholars have been abroad for training, research collaboration andacademic exchanges. On the other hand, more thank 150 foreignexperts and scholars have been invited to visit our laboratory forexchanging clinical experiences, giving lectures and joiningresearch collaboration. Three international conferences ongastroenterology were successfully organized by our laboratory in1996,2000 and 2005, respectively.


145 Middle Shandong Road,Shanghai200001,China






Dr.Fanggraduated from Jining Medical College of Medicine on 1984, got aMaster degree from Nanjing TCM University on July 1990, andreceived his Ph.D and M.D.degrees from Shanghai Second MedicalUniversity on July 1996. He worked at GI Division, University ofConnecticut Health Center, USA as a visiting scholar from Sept 1998to July1999, he also worked at NCI/NIH,USA from Aug 1999 to Oct2001; he was a research fellow in Cancer Center, University ofMichigan at Ann Arbor, USA on 2004.


His groupfocuses upon the studies about epigenetic modification and cellsignaling pathway during GI carcinogenesis. They performpreclinical investigations in cell, molecular, and animal models,and in early phase human clinical trials. Their overall goalis to prevent the formation of human GI cancer metastasis, and thusdeath from GI cancer.


1. got BESTPAPER PRIZE at 1996 Shanghai International Conference ofGastroenterology; 

2.< effectof folic acid and butyrate on the tumorigenesis and prevention ofgi cancer> received The Second Prize for China's 2008 StateScientific and Technological Progress Awards


1. Xiong H,Chen ZF, Liang QC, Du W, Chen HM, Su WY, Han ZG, Chen GQ, FangJY(Corresponding author). Inhibition of DNA methyltransferaseinduces G2 cell cycle arrest and apoptosis in human colorectalcancer cells via inhibition of JAK2/STAT3/STAT5 signaling. J CellMol Med, 2009; Jan 16. PMID: 19175468

2. Xiong H, Zhang ZG, Tian XQ, Sun DF, Zhang YJ, Lu R, Liang QC,Chen YX, Fang JY(Corresponding author). Inhibition of JAK1, JAK2and STAT3 signaling induces apoptosis, cell cycle arrest andreduces tumor cell invasion in colorectal cancer cells. Neoplasia,2008;10:287-97

3. Lu R, Wang X, Chen ZF, Sun DF, Tian XQ, Fang JY(Correspondingauthor). Inhibition of the extracellular signal-regulatedkinase/mitogen-activated protein kinase pathway decrease DNAmethylation in colon cancer cells. J Biol Chem, 2007;282:12249-59

4. Fang JY(Corresponding author), Lu R, Mikovits JA, Cheng ZH, ZhuHY, Chen YX,Lu LG. Recombinant DNA methyltransferase 1 constructsregulate expression of hMSH2 and hMLH1 in human colon cancer cellline SW1116. Cancer Lett,2006;233:217-25

5. Fang JY(Corresponding author), Richardson BC. The extracellularsignal regulated kinase- mitogen-activated protein kinasessignaling pathway and human colorectal cancer. Lancet Oncol,2005;6:322-7